Journal
MUSCLE & NERVE
Volume 61, Issue 2, Pages 156-162Publisher
WILEY
DOI: 10.1002/mus.26750
Keywords
Becker muscular dystrophy; behavioral; cognitive impairment; dystrophin; emotional; fluoxetine; genetics; learning disabilities; neurodevelopmental; pharmacotherapy
Categories
Ask authors/readers for more resources
Introduction Becker muscular dystrophy (BMD) results in decreased dystrophin with implications for mental health. Methods This is a retrospective case series of neurodevelopmental, behavioral, and emotional symptoms and respective pharmacotherapies of 70 patients with BMD. Results Fifty-four (77.1%) patients exhibited at least one symptom, and 19 (27.1%) patients exhibited four or more symptoms. The most prevalent symptoms were specific learning disabilities or special education needs (31.4%), inattention/hyperactivity (35.7%), language/speech delays (35.7%), and emotional or behavioral dysregulation (38.6%). Fisher's exact tests indicated that anxiety was more prevalent with mutations upstream of exon 30 (P = .049), but the prevalence of other symptoms did not differ with respect to mutation sites. Similarly, the number of symptoms individual patients with BMD exhibited did not differ with respect to mutation sites. Seventeen (24.3%) patients required pharmacotherapy to manage symptoms. Discussion Neurodevelopmental, behavioral, and emotional symptoms are prevalent in patients with BMD regardless of dystrophin gene mutation site.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available